Margarida Maia, PhD,  science writer—

Olgram has raised €1.5 million (about $1.77 million) in seed funding from investors to speed its development of antibiotics to clear persistent bacteria responsible for chronic, repeat infections. The company’s immediate focus is cystic fibrosis (CF), a disease characterized by chronic bacterial infection in the lungs. In a…

Health regulators in Australia have approved Trikafta (elexacaftor/tezacaftor/ivacaftor) to treat people with cystic fibrosis (CF), ages 12 years and older, who have at least one copy of the F508del mutation in the disease-causing gene, Vertex Pharmaceuticals, the therapy’s developer, announced. “We are delighted” that Trikafta is now…

Trikafta, a medication that combines three different therapies (elexacaftor/tezacaftor/ivacaftor), is safe and effective in children with cystic fibrosis (CF) ages 6 to 11 who have certain genetic mutations, results from a Phase 3 clinical trial show. The U.S. Food and Drug Administration (FDA) recently accepted for review a…

Parents of children and young adults with cystic fibrosis (CF) in Ontario sent a video appeal to the head of their province’s government, asking the premier to quickly expand prescription criteria that limits their access to key therapies by Vertex Pharmaceuticals. Two of the three gene modulating treatments noted…

Two bacterial species known to be frequent sources of lung infection in people with cystic fibrosis (CF) — Pseudomonas aeruginosa and Staphylococcus aureus — can feed each other with a nutrient called purine that both need to thrive, a study shows. Such interaction could determine the course of…